MK-677 and muscle gain: what the studies actually show

What did @drmikeisraetel actually say?

Dr. Mike Israetel laid out a fairly nuanced case for MK-677, a ghrelin receptor agonist that raises growth hormone and IGF-1 levels. His core argument: most of the weight you gain on the drug is not muscle. He estimated users might see 12 pounds on the scale over 12 weeks, but predicted "half of that's going to float off after a few weeks" once water retention normalizes. His net muscle estimate was roughly three pounds over a 12-week cycle. He also made a pointed safety comment, saying the drug is "not going to kill you" but is also "not a health elixir." That is a more honest framing than most MK-677 content online, which tends to hype the compound without mentioning that most visible gains are temporary fluid shifts.

Does the science back this up?

On the water retention point, yes, pretty solidly. The growth hormone-IGF-1 axis is well documented to promote sodium and water retention through renal tubular mechanisms. Johannsson et al. (1999, Journal of Clinical Endocrinology and Metabolism) demonstrated significant fluid retention in adults receiving GH replacement, with edema being one of the most common reported side effects. MK-677 replicates this downstream hormonal environment, so the claim that subcutaneous and intramuscular water accumulates is biologically plausible and consistent with what researchers have observed.

On actual muscle accrual, the evidence is thinner. Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) studied two years of MK-677 in healthy older adults and found modest lean mass increases, but distinguishing true myofibrillar growth from water-laden lean tissue is methodologically difficult in most of these trials. The three-pound muscle estimate Israetel offers is not unreasonable for a trained individual combining resistance training with MK-677, but it is speculative rather than confirmed by controlled trial data.

What did they get wrong (or right)?

Credit where it is due: Israetel correctly framed most visible scale weight as transient fluid, not muscle. That is accurate and rare candor in this content space. His inflation-then-deflation model of weight gain on GH-raising compounds is consistent with published literature.

Where he gets shakier is the breezy safety framing. Saying MK-677 is "not that terrible for your health" glosses over some real concerns. Prolonged elevation of IGF-1 is associated with increased cancer cell proliferation risk in observational data, and MK-677 reliably raises fasting glucose and can worsen insulin sensitivity. Nass et al. (2008, Annals of Internal Medicine) found that two years of MK-677 in elderly subjects increased insulin resistance and was associated with a higher rate of congestive heart failure. That study was halted early. Calling a drug that triggered early trial termination "not that terrible" undersells the risk profile for vulnerable populations.

His comparison to other muscle-building drugs that leave you "jacked in a coffin" is colorful but imprecise. Anabolic steroids have a well-characterized risk-benefit profile depending on dose and duration. Lumping everything into a binary of "this won't kill you" versus "death drugs" is not a framework that helps anyone make an informed decision.

What should you actually know?

MK-677 is not approved by the FDA for muscle building, anti-aging, or any consumer indication. It is an investigational compound. That matters because it means quality control, dosing standardization, and long-term safety data are all limited compared to approved therapeutics.

The weight gain Israetel describes, roughly 12 pounds on the scale, three pounds of which might be muscle, is plausible but context-dependent. Training status, diet, sleep quality, and baseline hormone levels will all influence outcomes. Someone sedentary getting adequate sleep will respond differently than a trained athlete in a caloric surplus.

The insulin resistance concern is not hypothetical. MK-677 elevates growth hormone pulsatility, and chronic GH elevation antagonizes insulin signaling. If you have prediabetes, a family history of type 2 diabetes, or metabolic syndrome, this compound carries meaningful risk that a TikTok summary cannot adequately convey.

Anyone considering peptide therapy of any kind should have a baseline metabolic panel, including fasting glucose and HbA1c, and should be monitored by a clinician who can interpret changes in those markers over time. A 12-week cycle without lab monitoring is not a responsible protocol.